Connecticut Pub. Act 23-171 Disclosure

NUVESSA® (metronidazole vaginal gel 1.3%)

Alembic Therapeutics LLC ("Alembic") provides the following information to Connecticut prescribers and pharmacists in accordance with Conn. Pub. Act 23-171.

The pricing information below reflects Alembic's Wholesale Acquisition Costs ("WAC") for Alembic's product(s) listed below. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the price(s) listed, depending, for example, on how the customer purchases the product(s), the availability of discounts, the wholesaler/distributor, and/or other charges.

WAC for Alembic's Product

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WAC
Nuvessa (metronidazole vaginal gel 1.3%)	0642-7466-05	Intravaginal gel/1.3%	$223.85

No Data on Variations Among Different Racial and Ethnic Groups

Pursuant to Connecticut Public Act No. 23-171, Alembic must also disclose any available data regarding variations in PIVYA's effectiveness or safety profile among different racial and ethnic groups.

Statement of Data Availability: No clinical data is available to determine whether the effectiveness or safety profile of PIVYA varies among different racial and ethnic groups.

Clinical Trial Baseline: The U.S. Food and Drug Administration (FDA) approval of PIVYA was based on controlled clinical trials assessing its efficacy against specific bacterial pathogens. The potential effects of race, ethnicity, age, or sex on the pharmacokinetics, pharmacokinetics-pharmacodynamics, or clinical efficacy of PIVYA **have not been evaluated**.

Copies of the full Prescribing Information are available through the Alembic sales representative who has provided you with this disclosure form as well as online at https://pivya.com/assets/pdf/pivya-prescribing-information.pdf?1

© 2026 Alembic Therapeutics LLC
NUVESSA and NUVESSA logo are registered trademarks of Alembic Therapeutics LLC

Pricing Effective as of November 1, 2026